Square Pharmaceuticals PLC, the top drug manufacturer in the country, has chosen to invest Tk650 crore to expand its business and enhance its presence in the pharmaceutical market.
The decision was made by the company during a board meeting on Wednesday.
As per the price sensitive statement from the company, Square Pharma’s board has proposed a historic 120% cash dividend for FY25.
In order to approve the dividend, the company has set the annual general meeting for 15 December and established the record date as 16 November.
In the previous fiscal year, the consolidated net profit reached Tk2,397 crore, with earnings per share at Tk27.04, reflecting a 15% increase from the prior year.
